围手术期化疗高危软组织肉瘤的预后分类改进
本研究基于一项比较不同围手术期化疗方案的随机对照试验数据,分析高危软组织肉瘤患者,用Sarculator列线图计算10年总生存概率(pr-OS)和远处转移发生率(inc-DM),并评估RECIST与Choi标准肿瘤反应。结果显示Sarculator可将患者分为三个预后组,且Choi反应与预后分层相关。
要点
- Sarculator列线图可改进高危STS围手术期化疗患者的预后分类。
- Choi标准肿瘤反应可进一步分层生存,RECIST未显示此作用。
核心结论
- Sarculator识别接受围手术期化疗的高危STS患者结局差异并改进预后分类,且与不同肿瘤反应模式相关,未来新辅助化疗试验应考虑用预后工具筛选入组患者。
研究设计与样本
- 分析一项研究不同围手术期化疗方案的随机对照试验中纳入的高危STS患者数据。
主要发现
- 低、中、高pr-OS组10年OS分别为0·42(95%CI 0·32-0·52)、0·63(95%CI 0·53-0·72)、0·78(95%CI 0·68-0·85)。
- 中pr-OS组(HR 0·51,P = 0·002)和高pr-OS组(HR 0·28,P < 0·001)较低pr-OS组死亡风险显著更低。
- 中pr-OS组Choi部分肿瘤反应率更高,Choi而非RECIST反应可分层pr-OS各组生存,尤其在中至低pr-OS患者中。
- 10年inc-DM分析结果与pr-OS一致。
临床怎么用
- 可考虑用Sarculator对高危STS患者进行预后分层,并结合Choi标准评估肿瘤反应以辅助临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with extremity and trunk wall soft tissue sarcoma (STS) with high malignancy grade and size >5 cm are at high-risk of death. This risk varies depending also on other patient and tumour features, including histologic subtype. This study investigated whether a prognostic nomogram can improve risk assessment of these patients. METHODS: Data from high-risk STS patients enrolled in a randomised controlled trial investigating different perioperative chemotherapy regimens were analysed. Ten-year probability of overall survival (OS) and incidence of distant metastasis (DM) were computed using the prognostic nomogram Sarculator (pr-OS and inc-DM, respectively). Tumour response according to RECIST and Choi criteria was also investigated. FINDINGS: Variation in pr-OS and inc-DM were observed and patients stratified in three prognostic groups. The 10-year OS in the low, intermediate, and high pr-OS categories were 0·42 (95%CI 0·32-0·52), 0·63 (95%CI 0·53-0·72), and 0·78 (95%CI 0·68-0·85), respectively. Patients in the intermediate (HR 0·51, P = 0·002) and high (HR 0·28, P < 0·001) pr-OS categories were at statistically significant lower risk of death compared with those in the low pr-OS category. Higher rate of Choi partial tumour responses were detected in intermediate pr-OS category. Tumour response according to Choi but not to RECIST criteria stratified patient survival of pr-OS categories, particularly for patients with intermediate to low pr-OS. Analyses conducted for 10-year inc-DM were consistent with results for pr-OS for prognostic value of Sarculator predictions and Choi tumour response. INTERPRETATION: Sarculator identifies variations in outcomes of high-risk STS treated with perioperative chemotherapy and improve prognostic classification, which is also associated with different patterns of tumour response, an outcome that further stratifies survival particularly for patients predicted at higher risk. Future trials investigating neoadjuvant chemotherapy should consider prognostic tool for selecting patients to be enrolled. TRIAL REGISTRATION NUMBER: European Union Drug Regulating Authorities Clinical Trials No. 2004-003979-36.
引用
- Pasquali S, Colombo C, Pizzamiglio S, et al. High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. Eur J Cancer. 2018. PMID: 29475197. doi:10.1016/j.ejca.2018.01.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。